Glenmark - Technical and Fundamental Analysis

fundamental story remains supported by its pharma-focused business, improving growth prospects and a diversified product portfolio across key therapeutic segments. The company’s ability to strengthen its branded and specialty portfolio remains an important long-term driver, while earnings growth and margin improvement will be key factors to track. Technically, the setup has turned constructive after a positive moving-average crossover, with the 20-DMA at around ₹2,266 crossing above the 50-DMA near ₹2,236. More importantly, both moving averages are now sloping upward, indicating that the underlying trend is gaining strength rather than simply experiencing a short-term bounce. The stock is trading comfortably above both averages and has reclaimed the ₹2,300 zone, keeping the near-term structure bullish. I would look at ₹2,260–2,270, around the 20-DMA, as the first meaningful dip-support zone, while ₹2,230–2,240 around the 50-DMA becomes the deeper support area. On the upside, the ₹2,350–2,400 zone is the immediate resistance band; a sustained breakout above ₹2,400 can open the way toward the previous highs around ₹2,450 and potentially higher. For now, I would maintain a positive bias as long as the stock continues to hold above its rising 20-DMA and 50-DMA.